妊娠期宫内暴露于抗TNFα药物治疗炎症性肠病的长期安全性:欧洲多中心TEDDY研究结果
该回顾性多中心队列研究纳入841名炎症性肠病母亲所生子女,其中388名(46%)在宫内暴露于抗TNFα药物。暴露组与未暴露组严重感染发生率相似(每人年1.6% vs 2.8%,风险比1.2,95%置信区间0.8-1.8)。结论认为宫内暴露于抗TNFα药物似乎不增加儿童短期或长期严重感染风险。
要点
- 宫内暴露抗TNFα药物与儿童严重感染风险无显著增加相关(风险比1.2,95%置信区间0.8-1.8)。
- 早产是唯一与严重感染风险升高相关的变量(2.5%,95%置信区间1.5-4.3)。
- 暴露组中位随访47个月,未暴露组68个月,两组严重感染发生率相似。
核心结论
- 宫内暴露于抗TNFα药物似乎不增加儿童短期或长期严重感染风险。
研究设计与样本
- 回顾性多中心队列研究,纳入841名炎症性肠病母亲所生子女,其中388名(46%)在宫内暴露于抗TNFα药物。
- 暴露组为妊娠期间或受孕前3个月内任何时间接受抗TNFα药物(伴或不伴硫嘌呤)的母亲所生子女。
- 非暴露组为妊娠期间或受孕前3个月内任何时间未接受抗TNFα药物或硫嘌呤的母亲所生子女。
主要发现
- 暴露组分娩后中位随访47个月,非暴露组68个月。
- 单变量和多变量分析均显示非暴露组与暴露组儿童严重感染发生率相似(每人年1.6% vs 2.8%,风险比1.2,95%置信区间0.8-1.8)。
- 多变量分析中,早产是唯一与严重感染风险升高相关的变量(2.5%,95%置信区间1.5-4.3)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The long-term safety of exposure to anti-tumor necrosis factor (anti-TNFα) drugs during pregnancy has received little attention. We aimed to compare the relative risk of severe infections in children of mothers with inflammatory bowel disease (IBD) who were exposed to anti-TNFα drugs in utero with that of children who were not exposed to the drugs. METHODS: Retrospective multicenter cohort study. Exposed cohort: children from mothers with IBD receiving anti-TNFα medication (with or without thiopurines) at any time during pregnancy or during the 3 months before conception. Non-exposed cohort: children from mothers with IBD not treated with anti-TNFα agents or thiopurines at any time during pregnancy or the 3 months before conception. The cumulative incidence of severe infections after birth was estimated using Kaplan-Meier curves, which were compared using the log-rank test. Cox-regression analysis was performed to identify potential predictive factors for severe infections in the offspring. RESULTS: The study population comprised 841 children, of whom 388 (46%) had been exposed to anti-TNFα agents. Median follow-up after delivery was 47 months in the exposed group and 68 months in the non-exposed group. Both univariate and multivariate analysis showed the incidence rate of severe infections to be similar in non-exposed and exposed children (1.6% vs. 2.8% per person-year, hazard ratio 1.2 (95% confidence interval 0.8-1.8)). In the multivariate analysis, preterm delivery was the only variable associated with a higher risk of severe infection (2.5% (1.5-4.3)). CONCLUSIONS: In utero exposure to anti-TNFα drugs does not seem to be associated with increased short-term or long-term risk of severe infections in children.
引用
- Chaparro M, Verreth A, Lobaton T, et al. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. Am J Gastroenterol. 2018. PMID: 29460920. doi:10.1038/ajg.2017.501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。